Rational use of pharmacogenetic and pharmacogenomic data in post marketing innovation

• In: Post-Marketing innovation in Drug Development (SIG Pharmacoeconomics/Pharmacoepidemiology and Industrial Pharmacy Section) on Tuesday, 7 September 2004, 14:00-17:00
• At: New Orleans (USA) (2004)
• Type: Presentation
• By: DAWSON, Bill (Bionet Ltd, Alton, Hants, United Kingdom)
• Abstract:

  Many medicines do not work equally well in the total patient population for a given indication. Modern genomic science suggests that this may be a result of variation in specific drug targets where single nucleotide polymorphisms may change responsiveness. In addition, the ability of any species to handle xenobiotics has a genetic basis, which

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login